Results 141 to 150 of about 86,778 (305)

The actions of human atrial natriuretic factor on hepatic arterial and portal vascular beds of the anaesthetized dog [PDF]

open access: yes, 1990
1. The vascular actions of atrial natriuretic factor (ANF) have been assessed with other vasoactive agents on the hepatic arterial and portal vascular beds of the anaesthetized dog. 2.
Dhume, V. G.   +3 more
core  

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population

open access: yes, 2007
Background: Measurement of B type natriuretic peptide and its N terminal prohormone (NTproBNP) can now be performed routinely by automated high-throughput immunoassays.
Barnes, S.C.   +5 more
core   +1 more source

Flexible wearable electronics for cardiovascular monitoring from surface signals to deep physiological insights

open access: yesFlexMat, EarlyView.
This review organizes flexible wearable electronics for cardiovascular monitoring into four interconnected information layers: surface electrophysiology, hemodynamic sensing, vascular imaging, and biofluid biomarker analysis. This framework clarifies how electrical rhythm, vascular loading, structural and flow‐related features, and biochemical states ...
Qiao Chen   +5 more
wiley   +1 more source

Use of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in the emergency department

open access: yesEuropean Heart Journal. Acute Cardiovascular Care, 2022
Lori B Daniels   +2 more
openaire   +2 more sources

Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection

open access: yes, 2008
ObjectiveThe objective of the study was to determine perioperative B-type natriuretic peptide levels in infants and children undergoing bidirectional cavopulmonary anastomosis or total cavopulmonary connection, and the predictive value of B-type ...
Hsu, Jong-Hau   +7 more
core   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

B-type natriuretic peptide secretion following scuba diving

open access: yes, 2011
To examine the neurohormonal effects of a scuba dive, focusing on the acute changes in the plasma concentrations of the different peptide fragments from the B-type natriuretic peptide (BNP ...
Jens Peter Goetze   +17 more
core   +1 more source

Early gut microbial and metabolic dysregulation with subclinical cardiac alterations in a nonhuman primate model of Rett syndrome

open access: yesiMeta, EarlyView.
Longitudinal multi‐omics profiling of a nonhuman primate Rett syndrome (RTT) model reveals early systemic alterations. RTT monkeys exhibited postnatal growth retardation, intestinal structural abnormalities, and low‐grade systemic inflammation. Gut microbiome analysis showed delayed microbial maturation and age‐discordant dysbiosis, including altered ...
Ting Zhang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy